Hansoh Pharmac Hd 00001 Stock Current Liabilities
3KY Stock | EUR 2.16 0.06 2.70% |
HANSOH PHARMAC HD 00001 fundamentals help investors to digest information that contributes to HANSOH PHARMAC's financial success or failures. It also enables traders to predict the movement of HANSOH Stock. The fundamental analysis module provides a way to measure HANSOH PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HANSOH PHARMAC stock.
HANSOH |
HANSOH PHARMAC HD 00001 Company Current Liabilities Analysis
HANSOH PHARMAC's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
In accordance with the recently published financial statements, HANSOH PHARMAC HD 00001 has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The current liabilities for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
All Next | Launch Module |
HANSOH Fundamentals
Return On Equity | 0.14 | |||
Return On Asset | 0.063 | |||
Profit Margin | 0.27 % | |||
Operating Margin | 0.28 % | |||
Shares Outstanding | 5.92 B | |||
Shares Owned By Insiders | 81.92 % | |||
Shares Owned By Institutions | 7.99 % | |||
Price To Earning | 38.60 X | |||
Revenue | 9.97 B | |||
Gross Profit | 9.06 B | |||
EBITDA | 3.02 B | |||
Net Income | 2.57 B | |||
Cash And Equivalents | 13.73 B | |||
Cash Per Share | 2.32 X | |||
Total Debt | 92.75 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 6.43 X | |||
Book Value Per Share | 3.57 X | |||
Cash Flow From Operations | 2.39 B | |||
Earnings Per Share | 0.06 X | |||
Number Of Employees | 10.78 K | |||
Beta | 0.57 | |||
Market Capitalization | 11.47 B | |||
Z Score | 73.8 | |||
Annual Yield | 0.01 % | |||
Last Dividend Paid | 0.12 |
About HANSOH PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HANSOH PHARMAC HD 00001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HANSOH PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HANSOH PHARMAC HD 00001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HANSOH Stock
HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.